Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Colorectal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- September 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Ironwood Cancer and Research Centers Scottsdale · Chandler, AZ
California · 2
- City of Hope National Medical Center · Long Beach, CA
- Cancer and Blood Research Center, LLC · Los Alamitos, CA
Florida · 1
- Cancer Specialists of North Florida - Southpoint · Jacksonville, FL
Illinois · 1
- Insight Research Institute · Chicago, IL
Kentucky · 1
- Pikeville Medical Center · Pikeville, KY
Michigan · 1
- Cancer and Hematology Centers of Western Michigan · Grand Rapids, MI
North Carolina · 1
- Duke Cancer Center · Durham, NC
Tennessee · 3
- Tennessee Oncology PLLC - Chattanooga · Nashville, TN
- Tennessee Oncology, PLLC · Nashville, TN
- Vanderbilt University Medical Center · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.